What Синджарди treats: Main Uses and Benefits

Синджарди is used to provide supportive relief for adults and children aged 10 and older managing Type 2 Diabetes Mellitus (T2DM). It is generally applied in contexts where the persistent problem of chronic hyperglycemia is insufficiently managed by single-agent therapy, or when comprehensive blood sugar management is appropriate as an adjunct to diet and exercise. This combination is commonly used to help with managing the risk of serious complications associated with T2DM.

Key therapeutic areas include achieving more stable blood sugar, managing the risk of serious heart events and hospitalization for heart failure in patients with established heart disease, and providing support for those with chronic kidney disease (CKD). This broad application provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact Block

Quick Fact: Supports management of Systemic Imbalance
Supports stability in adults and children with T2DM who have unstable blood glucose levels and is considered relevant for those facing cardiovascular vulnerability or chronic kidney disease.

---

Regulatory References

1. DailyMed FDA Prescribing Information

Who can and cannot use Синджарди?

The eligibility for Синджарди (Empagliflozin/Metformin HCl) is strictly defined by regulatory authorities based on age, organ function, and current health status. The medicine is approved for use in adults and pediatric patients aged 10 years and older with Type 2 Diabetes Mellitus.

---

Absolute Contraindications (Must Not Use)

Use is contraindicated in patients with the following conditions:

• Severe Renal Impairment: Specifically, those with an estimated Glomerular Filtration Rate ( eGFR) below 30 mL/ min/1.73 m^2, End-Stage Renal Disease ( ESRD), or patients on Dialysis.
• Metabolic Acidosis: Including Diabetic Ketoacidosis ( DKA).
• Hypersensitivity: A history of a serious allergic reaction to either Empagliflozin, Metformin HCl, or any component of the drug.

---

Restrictions and Limitations

The medicine is not recommended for several populations, including patients with hepatic impairment and those with moderate renal impairment (eGFR < 45 mL/ min/1.73 m^2). Use is also not recommended during the second and third trimesters of pregnancy or while breastfeeding. Temporary discontinuation is required during acute illnesses or prior to certain procedures, such as iodinated contrast imaging, to prevent complications.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of the Empagliflozin/Metformin combination through required procedural restrictions, pharmacokinetic changes, and reinforced pharmacodynamic effects. The most critical constraint involves Iodinated Contrast Agents, which are formally a contraindication in patients with specific renal function limitations or acute conditions. Co-administration necessitates a mandatory temporary discontinuation before or at the time of the procedure, with the medicine being withheld for 48 hours afterward to prevent Metformin accumulation and related risk.

---

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Pharmacokinetic	Organic Cation Transporter (OCT) Inhibitors (e.g., Cimetidine)	Increase Metformin plasma concentrations and systemic exposure by reducing its renal clearance.
Pharmacodynamic	Insulin and Insulin Secretagogues	Increase the risk of hypoglycemia due to an additive blood sugar lowering effect.
Pharmacodynamic	Diuretics (e.g., Loop Diuretics)	Increase the risk of symptomatic hypotension and volume depletion.
Substance-Specific	Excessive Alcohol Intake	Formally documented to enhance the effect of Metformin on lactate metabolism, increasing the risk of lactic acidosis.

---

These documented interactions highlight the need for careful regulatory review when co-administering medicines that affect renal clearance pathways or have overlapping effects on blood glucose or volume status. Population-specific notes also indicate that geriatric patients and those with hepatic impairment may face heightened interaction risks.

Синджарди (Synjardy) is a combination product that exerts its action through two distinct, complementary pharmacodynamic mechanisms influencing glucose and energy metabolism.

Renal Glucose Excretion Modulation

This mechanism is driven by the SGLT2 (sodium-glucose co-transporter 2) inhibitor component. It selectively inhibits the SGLT2 protein located in the proximal renal tubules. This inhibition reduces the renal reabsorption of filtered glucose, which, in turn, increases urinary glucose excretion (glucosuria). This process drives an osmotic diuresis and natriuresis, resulting in a reduction of systemic plasma glucose concentration and a decrease in intravascular volume.

---

Hepatic and Peripheral Glucose Regulation

This mechanism is mediated by the biguanide component, which primarily decreases hepatic glucose production by reducing gluconeogenesis. Additionally, it increases cellular uptake and utilization of glucose in peripheral tissues by promoting insulin sensitivity. These actions modulate signaling sequences that influence systemic glucose levels and promote a shift toward reduced endogenous glucose release.

The fixed-dose combination of Empagliflozin and Metformin Hydrochloride is administered via the oral route as a film-coated tablet, following a twice-daily frequency for the immediate-release formulation. The medicine must always be taken with meals to reduce gastrointestinal effects associated with the Metformin component. Dosing is an individualized process determined by the patient's existing regimen but is strictly limited by established maximums. The total daily intake is not to exceed 25 mg of Empagliflozin and 2,000 mg of Metformin Hydrochloride.

Prior to starting treatment, it is necessary to perform an assessment of renal function to determine if the medicine can be initiated or if dose adjustments are necessary. For instance, initiation is not recommended if the estimated Glomerular Filtration Rate (eGFR) is below 45 mL/min/1.73 m^2, and specific maximum dose restrictions apply in certain eGFR ranges. The medicine is approved for the same dosing maximums in pediatric patients aged 10 years and older.

Procedurally, patients are instructed to swallow the tablets whole and follow specific guidelines for handling timing deviations. If a dose is missed, the dose should be taken immediately unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped; the dose should never be doubled. Furthermore, the protocol requires the medicine to be temporarily withheld for a specific period (e.g., three days) before certain major surgical procedures or when receiving iodinated contrast media. These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

The fixed-dose combination of empagliflozin and metformin (Synjardy) is studied as a treatment to help improve blood sugar (glycemic) control in adults and children (10 years and older) with type 2 diabetes, when used alongside diet and exercise.

---

Glycemic and Metabolic Outcomes

Clinical trials evaluated the components of the combination therapy in adults with type 2 diabetes whose blood sugar was inadequately controlled on metformin alone or in combination with other drugs. Key findings reported at 24 weeks include:

• HbA1c Reduction: Studies showed a statistically significant reduction in Glycated Hemoglobin ( HbA1c) levels compared to placebo when empagliflozin was added to metformin therapy.
• Body Weight and Blood Pressure: Research observed reductions in both body weight and systolic blood pressure when empagliflozin was used as an add-on to metformin.

---

Cardiovascular and Renal Protection

The empagliflozin component of this combination has been investigated in large-scale cardiovascular outcome trials (CVOTs). While the combination drug itself has not been studied for cardiovascular risk reduction, the empagliflozin monotherapy demonstrated a reduction in the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

• Additional Use: Empagliflozin is also indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.

Common questions about Синджарди (FAQ)

---

Q: What is the main difference between Synjardy and standard Metformin?

Synjardy is a fixed-dose combination of two active ingredients: Metformin and Empagliflozin. Empagliflozin is a second agent that works by increasing the removal of sugar through the urine. This combination provides complementary mechanisms to address high blood sugar, according to official product information.

---

Q: Is it true that Synjardy may help with weight reduction?

Official studies indicate that the Empagliflozin component, when added to Metformin therapy, has been associated with reductions in body weight. This is one of the metabolic outcomes documented in the research used to support the medicine.

---

Q: Can Synjardy affect kidney function?

Regulatory guidelines require renal function assessment before initiation, as the medicine is not recommended for starting in patients below a specific eGFR threshold. Additionally, the Empagliflozin component is indicated to reduce the risk of a sustained decline in eGFR and other outcomes in adults with chronic kidney disease who are at risk of progression.

---

Q: Is Synjardy associated with urinary or genital tract infections?

Common adverse reactions documented in regulatory sources include urinary tract infection and female genital mycotic infections. This occurs because the Empagliflozin component works by increasing glucose excretion through the urine, which creates a sugar-rich environment.

---

Q: Can Synjardy affect blood pressure?

Clinical research has observed reductions in systolic blood pressure. However, official documents state the medicine is associated with a risk of volume depletion, which can lead to symptomatic hypotension (low blood pressure), particularly in elderly patients or those taking diuretics.

---

Q: What do the doses combined on the Synjardy package mean (e.g., 5 mg/1000 mg)?

The two numbers on the tablet packaging indicate the specific amount of each active ingredient in that tablet strength. The first number refers to the dosage of Empagliflozin, and the second number refers to the dosage of Metformin Hydrochloride, as defined in official labeling.

---

Q: Can Synjardy cause dehydration, and what should be done about it?

The medicine can cause volume depletion, which is a loss of body fluid that can lead to low blood pressure. Regulatory documents state that an assessment of volume status may be required before starting treatment, especially in elderly patients or those using diuretics.

---

Q: Is it possible to take Synjardy if I have kidney problems?

Use is contraindicated in patients with severe renal impairment ( eGFR below 30 mL/min/1.73 m^2). Initiation is not recommended if the eGFR is less than 45 mL/min/1.73 m^2. Regulatory instructions specify that renal function must be assessed prior to initiation and monitored regularly during treatment.

---

Q: How long does it take to see results from taking Synjardy?

The Empagliflozin component’s mechanism of increasing urinary glucose excretion results in an immediate reduction in plasma glucose levels upon administration. Clinical trials evaluated the reduction in blood sugar ( HbA1 c) levels over a period of 24 weeks.

---

Q: Are there any age restrictions for taking Synjardy (e.g., for elderly people)?

The medicine is approved for use in adults and pediatric patients aged 10 years and older. Regulatory documents note that elderly patients (age 65 and above) have a higher documented incidence of adverse reactions related to volume depletion and reduced renal function.

---

Q: What is known about the long-term safety profile of Synjardy?

Clinical studies have examined the long-term safety profiles of the individual component medications. Serious adverse reactions such as lactic acidosis and ketoacidosis are continually monitored. Official regulatory bodies require postmarketing studies to continue the evaluation of the safety of SGLT2 inhibitors.

---

Q: Can I stop taking Synjardy once my blood sugar levels normalize?

Official instructions provide specific guidance for temporarily stopping the medicine before certain procedures or when a patient is hospitalized for acute serious medical illnesses. The decision to permanently stop treatment is a clinical matter that requires professional evaluation.

---

Q: Does Synjardy affect Vitamin B12 levels in the body?

Official documents state that the Metformin component of the medicine may lower the amount of Vitamin B12 in the blood. Regulatory agencies recommend measuring hematologic parameters and Vitamin B12 levels at specified intervals during treatment.

---

Q: Does Synjardy affect cholesterol?

Official documents have documented an increase in LDL-C (low-density lipoprotein cholesterol) as a possible effect of treatment. Increases in total cholesterol, HDL cholesterol, and non-HDL cholesterol have also been observed in research.

---

Q: Can Synjardy affect bone density or joints?

Joint pain (arthralgia) is listed in regulatory documents as a possible adverse reaction. The official labeling for Empagliflozin continues to be evaluated regarding a definitive link to bone density or fracture risk.

---

Q: Why might Synjardy be prescribed to patients with chronic kidney disease?

The Empagliflozin component of this medicine is indicated to reduce the risk of a sustained decline in eGFR, end-stage kidney disease, and hospitalization in adults with chronic kidney disease who are at risk of progression. This indication is separate from the contraindications that exist for severe renal impairment.

How to Store and Dispose of Synjardy

Synjardy (empagliflozin and metformin hydrochloride) must be stored under specific conditions to maintain product stability, as detailed in regulatory documents.

Official Storage and Handling Requirements

Requirement	Specific Condition
Temperature	20 C to 25 C (68 F to 77 F)
Temperature Excursions	Permitted between 15 C and 30 C (59 F and 86 F)
Child Safety	Must be kept out of the reach of children.

Disposal Instructions

Unused or expired Synjardy tablets must be handled and disposed of according to local regulatory requirements for pharmaceutical waste. The official labeling states the medicine should not be disposed of via household waste or wastewater to protect the environment.